Accelerated Approval Of Lilly’s Alzheimer’s Drug Could Last About 15 Months, CEO Says
Executive Summary
Lilly expects results from donanemab ongoing confirmatory trial in 2023, while Biogen has nine years to finish its postmarket study. CEO David Ricks discusses impact of aducanumab approval backlash, pricing and national coverage decision at STAT summit.